Skip to NavigationSkip to content

Astellas confirms Kenji Yasukawa as new President and CEO

Published on: 07/02/18

Japanese pharmaceutical firm Astellas has announced that its Board of Directors has approved the selection of current Chief Strategy Officer and Chief Commercial Officer Kenji Yasukawa as its new President and CEO. He will take over from current CEO Yoshihiko Hatanaka on 1 April, who has led the company since 2011 and will go on to become Chairman of the Board.

Yasukawa boasts a career in the industry spanning over 30 years, beginning in 1986 when he joined Yamanouchi Pharmaceutical. Following the formation of Astellas from the merger of Yamanouchi and Fujisawa Pharmaceutical in 2005, he has held a range of executive roles, including      Therapeutic Area Head, Urology for Astellas Pharma Europe and Vice President of Product & Portfolio Strategy. He has served as the company’s CSO since 2012, and as CCO sicne 2017.

At a time when nine-month sales declined by under 1% to 999.4 billion Japanese yen ($9.2 billion) and profits slipping 20.2% for the same period, the company said that the leadership change would “enable Astellas to vigorously pursue the new strategic plan, which is set to start in the fiscal year 2018, aiming to realise the Astellas’ vision of being on the forefront of healthcare change to turn innovative science into value for patients.”

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches